Biotinylated epidermal growth factor: a useful tool for the histochemical analysis of specific binding sites.
Epidermal growth factor (EGF) was labelled with biotin via modification of either the amino or carboxyl groups, using suitable reagents, namely biotinyl-N-hydroxysuccinimide ester or biotinamidocaproyl hydrazide. To assure that the specific binding capacity of EGF is retained despite its chemical modification, displacement of the EGF by biotinylated derivatives in a routine binding assay was performed. The inhibitory potency compared to unmodified EGF was only slightly reduced. This result is the prerequisite for testing the usefulness of biotinylated EGF in histochemistry. The biotinylated probes were applied to sections of human tumour tissue and of monkey organs (liver, kidney, uterus of Cynomolgus and Rhesus monkey) to localize the specific binding sites for EGF. Formalin-fixed, paraffin-embedded tissue sections were deparaffinized and incubated with the probes at a concentration of 10 micrograms ml-1 at room temperature for 60 min. Specific binding of the EGF was visualized by the avidin-biotin techniques (ABC). A positive reaction in conjunction with appropriate controls by competitive inhibition was seen for all monkey tissue sections and for the following number of cancer cases: breast carcinoma: 7/10; mesothelioma: 2/4; lung carcinoma: 1/3; colon carcinoma: 1/3. The staining properties were similar for both types of probes that differed in the functional group that is involved in modification by biotin attachment. However, the batches with modification of the amino groups stained more intensely and more distinctly than the carboxyl modified EGF. Overall, the data indicate that the ligand properties of the EGF are not impaired by biotinylation of the two types of functional groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Kayser
K
K
E. Merck, Frankfurter, Darmstadt, Germany, FRG.
Weisse
G
G
Gabius
H J
HJ
Hintze
T
T
D000818:Animals; D001665:Binding Sites; D001710:Biotin; D001943:Breast Neoplasms / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D003110:Colonic Neoplasms / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000032:analysis / Q000378:metabolism; D005260:Female; D006651:Histocytochemistry / Q000379:methods*; D006801:Humans; D007668:Kidney / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D008099:Liver / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D008175:Lung Neoplasms / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D008252:Macaca fascicularis; D008253:Macaca mulatta; D014599:Uterus / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure
D004815:Epidermal Growth Factor; D001710:Biotin; D066246:ErbB Receptors